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AbstrAct:
The regulation of steroidogenic hormone receptor-mediated activity plays an important role in the development of 
hormone-dependent cancers. For example, during prostate carcinogenesis, the regulatory function played by the androgen 
receptor is often converted from a growth suppressor to an oncogene thus promoting prostate cancer cell survival and 
eventual metastasis. Within the cytoplasm, steroid hormone receptor activity is regulated by the Hsp90 chaperone in 
conjunction with a series of co-chaperone proteins. Collectively, Hsp90 and its binding associates form a large heteromeric 
complex that scaffold the fully mature receptor for binding with the respective hormone. To date our understanding 
of the interactions between Hsp90 with the various TPR domain-containing co-chaperone proteins is limited due to a 
lack of available structural information. Here we present the stable formation of Hsp902-FKBP521- HOP2 and Hsp902-
FKBP521-p232-HOP2 complexes as detected by immunoprecipitation, time course dynamic light scattering and electron 
microscopy. The simultaneous binding of FKBP52 and HOP to the Hsp90 dimer provide direct evidence of a novel 
chaperone sub-complex that likely plays a transient role in the regulation of the fully mature steroid hormone receptor.
IntroductIon
The activation of steroid hormone receptors plays an 
important role in the development of hormone-dependent 
cancers. For example, in a healthy prostate the androgen-
bound receptor functions through a reciprocal paracrine 
interaction between the epithelial and stromal cells 
which activates a transcriptional cascade that ultimately 
stimulates the proliferation of epithelial cells [1]. Under 
physiological conditions, ligand-bound androgen 
receptor prevents the overgrowth of the epithelial 
compartment by suppressing cell proliferation and by 
triggering cellular differentiation [1-4]. However, during 
prostate carcinogenesis, the regulatory function played by 
the androgen receptor is often converted from a growth 
suppressor to an oncogene which in turn stimulates 
prostate cancer cell survival and proliferation [1, 5, 6].
Within the cytoplasmic milieu, steroid hormone 
receptor activity is tightly regulated by a series of 
chaperones that stabilize the receptor and maintain its 
ability to bind hormone [7-10]. These primarily include 
the Heat shock family of proteins Hsp40, 70 and 90, 
of which Hsp90 plays the most pivotal role in the later 
stages of hormone receptor maturation [11, 12]. Hsp90 
is the most abundant molecular chaperone in the cytosol 
comprising roughly 1-2% of the cytosolic protein fraction 
[13]. Hsp90 binds with its client and associate proteins 
through short hydrophobic peptide sequences and 
facilitates protein folding through the shuffling between 
multiple ATP-dependent conformations [14, 15]. This 
activity is dependent on the dimeric nature of Hsp90, 
which is mediated by a high-affinity dimerization domain 
in the carboxy-terminal end of the protein [16, 17].
Hsp90 is not solely responsible for the maturation 
of the steroid hormone receptor but requires a specific 
set of binding associates it uses as co-chaperones [14, 
18-21]. Collectively Hsp90 and its respective binding 
partners form dynamic multimeric assemblies in which 
the co-chaperones are replaced interchangeably at 
different stages of the steroid receptor cycle. In this 
cycle, the steroid receptor initially associates with Hsp40 
and Hsp70, before being passed on to Hsp90 through 
intermediate binding interactions with the Heat shock 
Organizing Protein (HOP) [22]. Once the receptor is 
bound to the Hsp90 dimer, ATP-binding triggers the 
dissociation of HOP, leading to the subsequent binding of 
the Hsp90-receptor complex to other co-chaperones such 
as p23 and the 52 kDa immunophilin FK506-binding Oncotarget 2011; 2:  43 - 58 44 www.impactjournals.com/oncotarget
Figure 1: The purification of steroid hormone receptor chaperones and co-chaperones. (A) A Laser excitation fluorescent 
detection chromatogram revealed the relative micro-fluidic migration positions of the molecular weight standards (values in kDa) depicted as 
a function of fluorescence versus time. (B) A similar laser excitation fluorescent detection chromatogram illustrating the migration positions of 
the p23 (red), FKBP52 (blue), HOP (cyan) and Hsp90 (green) proteins. The respective chromatographic spectra are staggered along the y-axis 
for purposes of clarity. (C) BIO-RAD Experion™ statistical analysis of the purified p23, FKBP52, HOP and Hsp90 proteins highlighting their 
respective migration times through the microfluidic channels of the Pro260 chips (seconds), as well as their estimated molecular weights (kDa) 
and relative degrees of homogeneity (%).Oncotarget 2011; 2:  43 - 58 45 www.impactjournals.com/oncotarget
protein (FKBP52) [22]. Once in this mature complex, the 
receptor is primed for binding with its respective hormone 
ligand which in turn triggers a conformational change 
exposing the receptor’s zinc-fingered DNA binding motifs 
to bind to the nuclear chromatin [23, 24].
As part of the mature chaperone complex, the 
small, acidic co-chaperone p23 binds directly to Hsp90 
in a nucleotide-dependent fashion [25]. It is the smallest 
component in the Hsp90 machinery (Mr 18,000 - 25,000) 
and was first discovered in complex with Hsp90 and the 
progesterone receptor [26, 27]. The complete cellular 
function of p23 has not been fully elucidated. However, 
in the context of steroid hormone receptor regulation, 
the binding of p23 to Hsp90 is believed to stabilize the 
ATP-bound state of Hsp90 by obstructing the nucleotide-
binding domains [28, 29]. A recent crystal structure of an 
Hsp902-p232 complex has confirmed this interaction in 
which p23 is seen bound to the amino-termini of Hsp90 
through hydrophobic interactions [28]. As a result, 
p23 stabilizes the conformational changes induced by 
ATP binding which triggers the subsequent binding of 
immunophilin proteins and the activation of the steroid 
hormone receptor to its high-affinity ligand-binding state 
[30-33].
FKBP52 is a large peptidyl-prolyl cis-trans 
isomerase (PPIase) immunophilin protein that carries the 
ability to bind to immunosuppressive drugs. Structurally, 
FKBP52 consists of carboxy- and amino-termini that each 
have distinct roles in steroid hormone receptor regulation. 
A tetratricopeptide repeat domain (TPR) at the carboxy-
terminus characterizes the binding surface for the well-
defined -EEVD sequence motif at the carboxy-terminus of 
Hsp90 [34-37]. However, FKBP52 may also interact with 
the middle-domain (MD) of Hsp90 at a hydrophobic patch 
surrounding Trp300 [38-40] as seen with the Cdk4 kinase 
[41]. The amino-terminus of FKBP52 is highlighted by 
the FK-1 and FK-2 domains. Of particular interest, the 
FK-1 domain is believed to be largely responsible for 
FKBP52-mediated potentiation of receptor efficiency by 
providing the binding surface for the receptor [34, 42, 43]. 
Mutagenesis studies have indicated this to be true for point 
mutations in and around the FK-1 domain. These findings 
reveal that FKBP52-mediated potentiation of receptor 
activity is significantly abrogated in glucocorticoid (GR), 
androgen (AR) and progesterone (PR) receptor models 
[34, 42-45]. The physiological significance of FKBP52 
has also been elucidated in knock out (KO) studies 
where male mice lacking the Fkbp4 gene that encodes 
for FKBP52 display several developmental defects such 
as having ambiguous external genitalia and dysgenic 
prostate and seminal vesicles [44, 46]. 
In addition to p23 and FKBP52, HOP also plays a 
distinct role in steroid hormone receptor regulation by 
acting as an intermediary between Hsp70 and Hsp90. 
HOP recruits Hsp90 to interact with preexisting receptor-
Hsp70 complexes, thus facilitating the well-articulated 
progression towards a fully mature receptor complex in 
which the receptor is primed for ligand-binding [7, 10, 11, 
33, 47]. Like FKBP52, HOP is a TPR domain-containing 
protein and characteristically bind to Hsp90 in a very 
similar fashion [48]. FKBP52 and HOP are believed to 
both carry the ability to bind to Hsp90 at multiple sites, 
doing so in a competitive fashion while interacting at 
separate stages in the receptor cycle [11, 22, 32, 49, 50]. 
To date, the structural architecture of the 
intermolecular interactions between Hsp90 and its 
respected co-chaperone binding associates is still poorly 
understood, despite recent crystallographic data of the 
Hsp902-p232 complex [28]. In particular, our understanding 
of the interactions between Hsp90 with the various TPR 
domain-containing proteins remains unclear due to the 
lack of available structural data. In the work presented 
here, the stable formation of an Hsp902-FKBP521-p232-
HOP2 complex was detected by immunoprecipitation, 
time course dynamic light scattering (DLS) and electron 
microscopy (EM). Our results highlight the simultaneous 
binding of FKBP52 and HOP to the Hsp90 dimer 
independently of nucleotide and the p23 co-chaperone. 
Collectively these results provide evidence of a novel 
chaperone complex that likely plays a transient role in the 
regulation of fully mature steroid hormone receptors. 
results
The purification of the p23, FKBP52, HOP and 
Hsp90 dimeric species
The constituent proteins for the formation of the 
Hsp902-FKBP521-p232-HOP2 complex were individually 
purified  using  a  number  of  column  chromatographic 
techniques. Automated electrophoresis was used to 
analyze each target protein on the basis of molecular 
weight as a function of microfluidic channel migration 
(Figure 1A-B). The percentage of target protein relative to 
the total protein per sample was measured to highlight the 
relative homogeneity of each sample (Figure 1C).
In the process of purifying the individual proteins 
prior to incorporating them into the Hsp902-FKBP521-
p232-HOP2 complex, it was revealed that each binding 
associate carries the ability to form a dimeric species. 
The elution positions of p23, FKBP52, HOP and Hsp90 
in a size-exclusion (SEC) chromatogram relative to 
sizing controls were indicative of each respective protein 
being present as a dimer (Figure 2A). Additionally, p23 
also eluted further downstream of its dimeric species as 
a monomer. The oligomeric states of each protein were 
validated against a linear regression derived from known 
standards and their well-resolved elution points from the 
Sephacryl S-200 column (Figure 2B). Oncotarget 2011; 2:  43 - 58 46 www.impactjournals.com/oncotarget
Figure 2: The existence of substrate dimers as observed by Sephacryl S200 size-exclusion chromatography. (A) During 
analytical size-exclusion chromatography experiments, the p23 protein (red) eluted as two distinct peaks representative of dimer and monomer 
species. The FKBP52 (blue), HOP (cyan) and Hsp90 (green) proteins each eluted as single isolated peaks. Colored stars representative of each 
individual protein line the x-axis to highlight the elution points relative to volume. The two p23 peaks are individually represented by a red 
(dimer) and a light red (monomer) star. (B) A linear regression was done on the respective elution positions of protein standards with well-
known molecular weights to interpolate the molecular weights of the target proteins from their elution positions. The colored triangles represent 
the interpolated molecular weight values derived from the linear regression (R2=0.88) while the colored circles denote molecular weight values 
derived from primary sequence information. Each protein is labeled to highlight its assumed multimeric conformation.Oncotarget 2011; 2:  43 - 58 47 www.impactjournals.com/oncotarget
Stoichiometries of the Hsp90 interactions
A  series  of  Native  PAGE  experiments  were 
conducted to assess the respective protein binding ratios 
of Hsp90 with p23 and the TPR domain-containing 
proteins.  It  was  revealed  that  a  significant  amount  of 
FKBP52 remained unbound when added to Hsp90 in a 
2:2 molar ratio (Figure 3). For this reason, FKBP52 was 
added to Hsp90 in a 1:2 molar ratio in all subsequent 
experiments. The molar binding ratios HOP and p23 have 
with Hsp90 were indecipherable by Native-PAGE due to 
the indiscernible size difference between the HOP and 
Hsp90 dimers and the seemingly weak affinity Hsp90 has 
for p23. As an alternative, the HOP and p23 proteins were 
added to Hsp90 in a 2:2 or dimer-dimer molar ratio based 
on recently published isothermal titration calorimetry 
studies and crystallographic data [22, 28].
FKBP52  and  HOP  can  bind  to  Hsp90 
simultaneously
A series of immunoprecipitation experiments were 
performed to investigate the binding of p23, FKBP52 
and HOP to the Hsp90 dimer using a monoclonal Hsp90 
antibody in conjunction with Protein A-Sepharose beads. 
Initially, a series of control experiments were executed 
to highlight the direct specificity of the Hsp90 antibody 
(Figure 4A). Subsequently the simultaneous binding of 
FKBP52 and HOP to Hsp90 was tested revealing that the 
two proteins act independently of one another and in a non-
competitive fashion (Figure 4B). Hsp90-bound antibody/
Protein A beads were treated with a five-fold molar excess 
of FKBP52 protein to completely saturate the designated 
FKBP52 binding sites on the Hsp90 particles. After 
thorough washing, the beads containing FKBP52 bound 
to Hsp90 were treated with a five-fold molar excess of 
HOP to determine if HOP could still bind. Executing the 
co-IP experiment in a step-wise fashion ensured that the 
proteins bound to the final bead pellets were representative 
of FKBP52 and HOP binding at two different locations 
on Hsp90 and not a mixture of species in which the two 
Figure 3: Stoichiometry of the Hsp90-FKBP52 interaction as determined by Native PAGE. When FKBP52 was added to Hsp90 
in a 1:2 ratio there was a noticeable upward shift in the position of the Hsp90 band in both the absence and presence of 5mM ATP, 20mM 
Na2MoO4. When added in a 2:2 ratio there fails to be an additional upward shift in the position of Hsp902-FKBP521 band, also illustrated by the 
large independent band of unbound FKBP52.Oncotarget 2011; 2:  43 - 58 48 www.impactjournals.com/oncotarget
proteins shared the same binding location (Figure 4B, lane 
4). Sequential co-IP was also performed where the Hsp90-
bound  beads  were  first  treated  with  a  five-fold  molar 
excess of HOP protein and then a five-fold molar excess 
of FKBP52 (Figure 4B, lane 8). It is important to note that 
in executing the co-IP experiments sequentially and in the 
presence of large molar excesses to saturate the respective 
binding sites on Hsp90 that the final bead pellet would 
reveal whether or not there is a competition for a single 
binding motif on Hsp90 when resolved by SDS-PAGE. 
Such a competition would be illustrated by the presence 
of only one band in addition to that of Hsp90, the identity 
of which would depend on which of the two TPR domain-
containing proteins had the highest binding affinity for 
Hsp90. Interestingly the aforementioned competition was 
not observed here, illustrating that FKBP52 and HOP can 
bind to Hsp90 independently of one another. 
A quantitative measure of binding stoichiometry of 
the Hsp90-HOP and Hsp90-FKBP52 interactions could 
not be derived from the intensity of the protein bands 
on the gel. However, the increased intensity of the final 
HOP protein bands compared to the final FKBP52 bands 
(Figure 4B, lanes 4 and 8) may suggest that the binding 
affinity that Hsp90 has for HOP is greater than that for 
FKBP52. It is also worth noting that the simultaneous 
binding of these TPR domain-containing proteins was 
independent of both ATP and p23 as both were absent in 
each experiment.
In an effort to determine the effect ATP has on the 
FKBP52 and HOP interactions with Hsp90, additional 
Figure 4: Co-immunoprecipitation experiments reveal the simultaneous binding interactions of Hsp90 with the two TPR 
domain-containing proteins FKBP52 and HOP.  (A) Hsp90-antibody specificity. Three negative controls (-) were performed in which 
the protein A Sepharose-Hsp90 antibody beads were incubated with 40µg the p23, FKBP52 and HOP proteins respectively. A positive control 
(+) incorporating 40µg Hsp90 into the antibody-bead mixture was also executed. Hsp90 was used as the bait protein for the subsequent 
experiments. Hsp90 antibody heavy (HC) and light (LC) chains (far left) as well as the anticipated distribution of the target proteins (far right). 
(B) The simultaneous binding of FKBP52 and HOP to Hsp90. Lanes 1-3 represent excess unbound protein in the initial washout fractions when 
Hsp90 (lane 1) was treated with a five-fold molar excess of FKBP52 (lane2) followed by a five-fold molar excess of HOP (lane 3) in a step-wise 
fashion. Lanes 5-7 represent a similar experiment in which HOP was added prior to FKBP52. Lanes 4 and 8 both represent noticeable amounts 
of Hsp902-FKBP521-HOP2 complex that were bound to the final antibody/Protein A-Sepharose bead pellets. Both the control experiments and 
the saturation experiments were resolved by 10% SDS-PAGE.Oncotarget 2011; 2:  43 - 58 49 www.impactjournals.com/oncotarget
experiments were performed in the presence of a 5mM 
ATP and 20mM Na2MoO4 (Figure 5A). ATP was added 
to trap the Hsp90 dimer in its ATP-bound conformation 
from which we could determine the relative effects 
conformational changes have on complex formation. 
As a result, the binding of FKBP52 to Hsp90 appeared 
to be unaffected by the addition of ATP in both the 
Hsp902-FKBP521-p232 and Hsp902-FKBP521-p232-HOP2 
complexes (Figure 5A, lanes 1-2, 4-5). On the contrary, 
the relative degree of HOP binding to Hsp90 appears to 
be slightly diminished upon the addition of ATP (Figure 
5A, lanes 4-5). Interestingly, complex formation and the 
binding of p23, FKBP52 and HOP to Hsp90 was slightly 
enhanced when the binding solution was augmented 
with a 0.01% dose of non-ionic detergent (Figure 5A, 
lanes 3,6) [51]. This phenomenon was also captured 
in  Native-PAGE  experiments  in  which  the  addition  of 
non-ionic detergent appears to lead to a greater degree 
of Hsp902-FKBP521-P232 and Hsp902-FKBP521-p232-
HOP2 complex formation as indicated by the relative 
disappearance of the independent p23 band (Figure 5B). 
This is likely explained by the non-ionic detergent making 
the hydrophobic interaction between Hsp90 and p23 more 
thermodynamically favorable.
To further illustrate the simultaneous binding of 
FKBP52 and HOP to Hsp90, the Hsp902-FKBP521-p232-
HOP2 complex was passed through a Superose6 size-
exclusion column (Figure 6A). Only a small fraction of 
Hsp902-FKBP521 -HOP2 complex was able to survive 
the relatively harsh separation process as a result of the 
dynamic nature of its formation (Figure 6B-lane 1). Two 
additional peaks eluted downstream of peak one likely 
Figure 5: Co-immunoprecipitation and Native-PAGE experiments analyzing the relative degrees Hsp902-FKBP521-p232 
and Hsp902-FKBP521-p232-HOP2 complex formation in the presence of varying buffering conditions. (A) Lanes 1-3 represent 
the relative degree of Hsp902-FKBP521-p232 formation in the absence of ATP, in the presence of ATP and with ATP plus 0.01% of a non-
ionic detergent, respectively. Lanes 4-6 equate to the same buffering conditions withheld in lanes 1-3 but with the additional incorporation 
of HOP into the Hsp902-FKBP521-p232-HOP2 complex. The SDS-PAGE image is surrounded by two additional lanes indicating the relative 
position of the Hsp90 antibody heavy (HC) and light (LC) chains (far left) as well as the anticipated distribution of the target proteins (far 
right). Results illustrated by 10% SDS-PAGE (B) Native-PAGE results revealing a greater degree of p23 incorporation into the respective 
Hsp902-FKBP521-p232 (Lanes 1-2) and Hsp902-FKBP521-p232-HOP2 (Lanes 3-4) complexes in the presence of 0.01% non-ionic dodecyl-
maltopyranoside (Lanes 2 and 4).Oncotarget 2011; 2:  43 - 58 50 www.impactjournals.com/oncotarget
corresponding to unbound constituents (Figure 6B-lanes 2 
and 3). The molecular weight values of the protein species 
occupying the three chromatographic peaks was estimated 
to be approximately 575, 244 and 100 kDa respectively, 
when interpolated from a linear regression of molecular 
weight standards and their well-established elution 
positions from the Superose6 column (Figure 6C). p23 
did not stay in complex with the other components due to 
the fragility of the Hsp90-p23 interaction in the absence 
of ATP. Analytical size-exclusion chromatography could 
not be performed in the presence of ATP without the 
final  column  flow  becoming  occluded.  This  may  have 
resulted from the formation of large aggregates induced 
by conformational changes upon the addition of ATP or at 
the hand of the negatively charged nucleotide binding and 
accumulating onto the positively charged column matrix.
Hsp902-FKBP521-p232-HOP2  complex 
formation
Dynamic Light Scattering was used to track the 
formation of the Hsp902-FKBP521-p232-HOP2 complex as 
a function of the progressive increase in the hydrodynamic 
diameter (d. nm) of the complex. Initially each of the 
binding associates was measured separately to provide a 
baseline of their individual oligomeric states (Figure 7A). 
p23 had the smallest hydrodynamic diameter reading of 
7.5 nm while FKBP52 and HOP revealed very similar 
measurements of 13.9 and 13.7 nm respectively. Based on 
these results and the direct correlation between molecular 
weight and the volume of spatial occupancy, p23 was 
found to be present in its monomeric form while FKBP52 
and HOP were found as dimers. The Hsp90 dimer was 
subjected to DLS analysis resulting in a measured diameter 
of 17.6nm. DLS measurements of Hsp90 were executed 
Figure 6: Analytical Superose6 size-exclusion chromatography. (A) Size-exclusion chromatogram highlighting the separation of 
the Hsp902-FKBP521-HOP2 complex (peak 1) from unbound constituents (peaks 2 and 3). (B) 10% SDS-PAGE results of the three respective 
chromatographic peaks. (C) A linear regression of the Superose6 elution positions of protein standards was used to interpolate the molecular 
weights of the proteins eluting within the three peaks. The solid square and triangles represent the interpolated molecular weight values of 
the Hsp902-FKBP521-HOP2 complex and unbound constituents derived from the linear regression (R2=0.98).  The hollow square denotes the 
molecular weight value of the Hsp902-FKBP521-HOP2 complex derived from primary sequence informationOncotarget 2011; 2:  43 - 58 51 www.impactjournals.com/oncotarget
with and without ATP in an effort to capture differences 
in the hydrodynamic diameter of the ‘closed’ and ‘open’ 
conformations. However, the degree of variance between 
the two readings was too small to be regarded as outside 
of the range of instrumental accuracy.
To investigate the progressive formation of the 
Hsp902-FKBP521-p232-HOP2 complex as a function of 
time, DLS measurements were taken over a 75 minute 
incubation period in the presence of 5mM ATP, 20mM 
Na2MoO4 and 0.01% non-ionic detergent. The shift from 
unoccupied Hsp90 through to the complete complex 
occurred in the first 60 minutes with the hydrodynamic 
diameter increasing from 17.6 to 21.7 nm (Figure 7B). More 
importantly this increase in diameter correlates with a large 
volumetric increase as the hydrodynamic diameter and 
volume are exponentially related (V=4/3 r3). Interestingly, 
the degree of complex formation was stabilized within 
the first 60 minutes of the incubation. The hydrodynamic 
diameter of the complex did not increase after 60 minutes.
The formation of the Hsp902-FKBP521-p232-HOP2 
complex was also followed in a step-wise experiment 
revealing a gradual increase in the hydrodynamic diameter 
as more constituent proteins were added to Hsp90 (Figure 
8A). The addition of p23 to Hsp90 in a 2:2 ratio resulted 
in a slight increase from 17.6 to 17.7 nm. This seemingly 
insignificant  increase  is  likely  the  result  of  the  tight 
packing of the p23 molecules to the amino-termini of 
the Hsp90 dimer as indicated by recent crystallographic 
data [28] and as supported by the Co-IP results presented 
here. The incorporation of FKBP52 into the Hsp902-p232 
complex mixture resulted in an additional increase of 1.4 
nm from 17.7 to 19.1 nm. More notable was the large 
increase in hydrodynamic diameter from the 19.1 nm 
Hsp902-FKBP521-p232 complex to the 21.7 nm Hsp902-
FKBP521-p232-HOP2 complex (Figure 8A-right). The 2.6 
nm increase in hydrodynamic diameter resulting from the 
addition of HOP to the Hsp902-FKBP521-p232 complex 
indicated that HOP most likely bound to Hsp90 as a 
Figure 7: Hsp902-FKBP521-p232-HOP2 complex formation revealed by DLS. (A) Dynamic light scattering spectra of the p23 
(red), FKBP52 (blue), HOP (cyan) and Hsp90 (green) proteins illustrate diametric values that range between 7.6 and 17.6 nm as depicted 
on a logarithmic x-axis. Each individual constituent protein had a measured polydispersity values between 0.36-0.49.(B) The lateral shift in 
hydrodynamic diameter (increase in size) of the Hsp902-FKBP521-p232-HOP2 complex (contrasting shades of orange) over the course of a 75 
minute incubation at 30°C. Each individual sub-panel contains a bar graph representation of the DLS measurements outlined in the respective 
colors. Error bars depict the standard deviation within a 95% confidence interval.  Oncotarget 2011; 2:  43 - 58 52 www.impactjournals.com/oncotarget
dimer. Interestingly like HOP, FKBP52 also exists as a 
dimer in solution but seemingly dissociates and binds to 
Hsp90 as a monomer whereas HOP remains bound as a 
dimer. Additionally, the degree of complex formation was 
analyzed as a function of nucleotide availability revealing 
unchanged diameter readings even when the sample was 
deprived of ATP (Figure 8B). This was further supported 
by similar polydispersity readings of 0.47 (+/- 0.185) and 
0.45 (+/- 0.10) for the nucleotide-free and ATP-bound 
systems. As a control experiment, Hsp90 was analyzed in 
the presence of a 1:1 molar ratio of bovine serum albumin 
(BSA) of which it was no affinity for, to insure that the 
respective binding interactions with p23, FKBP52 and 
HOP were specific (Supplementary Figure 1).
In order to visualize the Hsp902-FKBP521-p232-HOP2 
complex, a sample of the complex was negatively-stained 
with 2% methyl-amine tungstate and examined by TEM 
(Supplementary Figure 2). At 100,000 x magnification the 
general shape of target particles within the micrographs 
can be characterized as elliptical and very reminiscent of 
the Hsp902-p232 X-ray structure [28]. As anticipated the 
particles representative of the Hsp902-FKBP521-p232-
HOP2 complex are noticeably larger than the unbound 
constituent proteins seen in the background. Some 
particles are oriented such that the separation in between 
the two Hsp90 monomers is visible and heavily stained 
(Supplementary Figure 2B). Other particles are oriented 
such that a noticeable amount of bulging density is seen 
protruding from one end of the Hsp90 dimer. We postulate 
that these protrusions are occupied by the binding of the 
FKBP52 and/or HOP TPR domain-containing proteins. It 
is worth noting that the binding of p23, FKBP52 and HOP 
Figure 8: Step-wise and nucleotide-based formation of the Hsp902-FKBP521-p232-HOP2 complex analyzed by DLS. (A) 
DLS captured the incremental rightward shift in increasing hydrodynamic diameter as the individual components of the complex were added 
to Hsp90 (green) in a step-wise fashion. p23 was first added to Hsp90 to yield the Hsp902-p232 complex with a polydispersity value of 0.42 
(+/- 0.11) (red). In subsequent steps, FKBP52 and HOP were added to form the Hsp902-FKBP521-p232 (blue) and Hsp902-FKBP521-p232-HOP2 
(cyan) complexes with polydispersity readings of 0.34 (+/- 0.12) and 0.40 (+/- 0.10) respectively. (B) The shift in hydrodynamic diameter of 
the Hsp902-FKBP521-p232-HOP2 complex from the initial unbound Hsp90 (green) through to the complete complex after 60 minutes in both 
the absence and presence of 5mM ATP, 20mM Na2MoO4 (red and blue respectively). The results depicted in both sub-panels (A and B, left) 
are graphed against a logarithmic x-axis. Additionally each individual sub-panel contains a bar graph representation of the DLS measurements 
outlined in the respective colors. Error bars depict the standard deviation within a 95% confidence interval.Oncotarget 2011; 2:  43 - 58 53 www.impactjournals.com/oncotarget
appears to hold Hsp90 in its ‘closed’ conformation. This 
conformational change is clearly visible when particles 
of the complex are compared to that of unbound Hsp90 
(Supplementary Figure 2C).
dIscussIon
In previous studies the human Hsp90 has been 
found to exhibit selective behavior for the binding of only 
one TPR domain-containing protein at a time [11, 49, 
50]. This behavior has also been observed for the yeast 
immunophilin and HOP homologues cpr6 and Sti1 [30, 
32]. In the work presented here, a number of biochemical 
and structural techniques were used to reveal the 
simultaneous binding of two TPR proteins to the Hsp90 
dimer. The binding of FKBP52 and HOP to Hsp90 appears 
to be extremely stable and can be facilitated under a 
number of environmental conditions as indicated by co-IP, 
DLS, Native PAGE and electron microscopy experiments. 
Yeast studies have postulated that the binding of the p23 
homologue Sba1 to Hsc82 is required prior to facilitating 
the binding of immunophilins [30, 32]. However, the 
co-IP,  Native  PAGE,  EM  and  analytical  size-exclusion 
chromatography results presented here indicate that the 
Hsp90-FKBP52 interaction occurs independently of p23 
and can occur readily in the absence of ATP. Apart from 
FKBP52, HOP appears to interact with Hsp90 in a non-
competitive fashion. Mutagenesis studies indicate that 
the binding of HOP to Hsp90 is nucleotide-independent, 
however this interaction can be weakened by the 
conformational changes induced by Hsp90’s adaptation 
into the ATP-bound state [22]. The immunoprecipitation 
results presented here support this notion to a limited 
extent; however, DLS results indicate that the Hsp90-
HOP interaction is also quite stable in the presence of 
5mM ATP and 20mM Na2MoO4. HOP also interacts with 
Hsp90 in the presence and absence of p23. These results 
strikingly contradict previous findings that stipulate that 
the binding of p23 occludes or alters the stability of the 
binding site for HOP on Hsp90 [11]. 
The stoichiometry and location of the interactions 
between FKBP52 and HOP with Hsp90 has previously 
been unclear and has lead to a number of ambiguities. 
While all of the substrates maintain the ability to dimerize 
in solution, co-crystallization experiments support the 
notion that FKBP52 binds to the -EEVD peptide located 
at the far carboxy-terminus of each Hsp90 in a 1:2 molar 
ratio [35]. This hypothesis is further supported the Native 
PAGE results presented here in which a 2:2 molar mixture 
of FKBP52 to Hsp90 resulted in a large fraction of 
unbound immunophilin compared to when the two entities 
were added in a 1:2 ratio. Much like FKBP52, HOP also 
has binding affinity for the -EEVD motif [36] and can 
bind alternatively to the hydrophobic middle-domain of 
Hsp90 [32, 39, 40]. The Hsp90-HOP interaction likely 
occurs in a 2:2 ratio as indicated step-wise DLS results 
presented here and by other biochemical analyses [22, 30, 
52]. The definitive stoichiometric binding ratios of the 
TPR domain-containing proteins with Hsp90 could not be 
Figure 9: General models of the chaperone-assisted regulatory cycle of steroid hormone receptors. (A) A cartoon schematic 
based on previous work hypothetically outlining the proteins involved in early, intermediate and mature complexes as the steroid hormone 
receptor is primed for binding with steroid hormone (SH) and an interaction with the hormone response elements (HRE) of the nucleus [22, 55, 
59]. (B) Our newly proposed mechanism in which HOP offers stability to a receptor-Hsp90-FKBP52-p23 heterocomplex in the absence of the 
Hsp40, Hsp70 and HIP proteins. Colored proteins indicate those that were under investigation in this study.Oncotarget 2011; 2:  43 - 58 54 www.impactjournals.com/oncotarget
resolved by our analytical size-exclusion chromatography 
experiments due to the strenuous nature of SEC 
separations. This issue can potentially be addressed 
through the use of ion mobility-mass spectrometric 
analysis (IM-MS), which has been used to reveal the 
subunit architecture of multimeric protein complexes of 
the bacterial replisome [53]. Additionally it is enticing 
to speculate over the Hsp90 binding positions of the 
FKBP52 and HOP proteins based on the particles in the 
presented EM micrographs. However, further structural 
investigations are required to reveal the arrangement of 
these intermolecular interactions.
In a recent model of the chaperone-mediated 
regulatory cycle of the steroid hormone receptor it has 
been postulated that there exists an intermediate assembly 
that is comprised of client protein (receptor) bound to the 
Hsp90, Hsp70, Hsp40, HIP and HOP proteins [54] (Figure 
9A). Upon the binding of ATP to Hsp90, the Hsp70, 
Hsp40, HIP and HOP proteins dissociate from Hsp90 and 
allow for the binding of immunophilins like FKBP52 or 
cyclophilin 40, and the p23 co-chaperone. This Hsp902-
FKBP521-p232 assembly characterizes a mature complex 
that is competent to facilitate hormone binding [22, 55]. 
While this model seems quite promising, the formation of 
the Hsp902-FKBP521-p232-HOP2 complex revealed here 
indicates that the intermediary role played by HOP is likely 
more substantial than previously described. HOP can 
remain bound to Hsp90 in the presence of immunophilin 
and p23 and likely offers stabilizing effects that were 
previously offered to the client protein by the proteins of 
the intermediate complex (Figure 9B). Once stabilized 
by Hsp90, HOP, FKBP52 and p23, it seems likely that 
ATP hydrolysis within Hsp90 triggers the dissociation of 
ligand-bound receptor for direct transport to the nucleus. 
However, it remains unclear as to whether or not the 
ligand-bound steroid receptor travels alone to the nucleus 
or with the accompaniment of Hsp90. Furthermore its 
remains to be seen whether a steroid receptor/Hsp90 
heterocomplex can permeate through the nuclear pores as 
has been demonstrated in the mineralocorticoid receptor 
system [56].
Despite the intrigue of the Hsp902-FKBP521-
p232-HOP2 complex and its possible involvement in the 
regulation of steroid hormone signal transduction, the 
importance of its formation remains to be seen in the 
presence of purified hormone receptor. Addressing this 
issue  is  a  daunting  task  largely  due  to  the  difficulties 
associated with producing functional amounts of stable 
client protein and the transient nature of the receptor-
chaperone binding interactions. It is likely that FKBP52 
is present in the mature receptor-chaperone complex as 
the FK-1 domain is believed to be largely responsible for 
FKBP52-mediated potentiation of receptor efficiency by 
providing the binding surface for the receptor [34, 42, 
43]. However, whether p23 and/or HOP remain bound 
to Hsp90 in the presence of the receptor remains unclear. 
Subsequent experiments using a purified steroid receptor 
sample are required to shed light on this question in 
hopes of further elucidating the roles p23, FKBP52 and 
HOP play in Hsp90-mediated steroid hormone receptor 
regulation.
METHODS
Protein expression and purification
The  human  FKBP52,  HOP  and  Hsp90α  proteins 
were expressed as amino-terminal 6x-Histidine-tagged 
constructs from the vectors pET28b-FKBP52, pET28b-
HOP, and pET28b-Hsp90α, respectively. The human p23 
co-chaperone was expressed as an untagged construct 
from the pET23-p23 vector. Escherichia coli BL21 (DE3) 
transformants were grown at 37°C to an A600nm optical 
density of 0.8 before protein expression was induced 
with  1mM  IPTG  at  30°C  for  several  hours.  The  cells 
were harvested by centrifugation and lysed in a 50mM 
Hepes, 10mM EDTA lysis, 1mM PMSF buffer pH 7.5 in 
conjunction with treatment with hen egg white lysozyme 
(Sigma) and multiple freeze/thaw cycles. 
The 6x-His-tagged FKBP52, HOP and Hsp90 
proteins were initially purified using a Ni2+ Sepharose 
HisTrap FF column (GE). The column was equilibrated 
and  washed  with  50mM  Hepes,  100mM  NaCl,  10mM 
MgCl2, 20mM Imidazole, 1mM PMSF, 0.02% NaN3 (pH 
7.5) and the respective proteins were eluted with a 250mM 
Imidazole step gradient. The target fractions for each of 
the respective proteins were further purified on a HiLoad 
Q-Sepharose 26/10 anion-exchange column (Amersham) 
that was equilibrated with 50mM Hepes, 10mM MgCl2, 
1mM  DTT,  1mM  PMSF,  0.02%  NaN3 (pH 7.5). The 
proteins were each eluted over a 400ml 0-600mM NaCl 
linear gradient [57]. Additionally, the HOP and Hsp90 
proteins were passed through a HiPrep Sephacryl S-200 
size-exclusion column (Amersham) that was equilibrated 
with 50mM Hepes, 150mM NaCl, 50mM KCl, 10mM 
MgCl2, 1mM DTT, 1mM PMSF, 0.02% NaN3 (pH 7.5). 
Despite having near absolute sample homogeneity after 
passage over the Q-Sepharose anion-exchange column, 
the FKBP52 sample was also subjected to treatment 
through the Sephacryl S-200 column for analysis of its 
multimeric conformational state.
The human p23 protein was initially purified over 
a quad-stack of 5ml DEAE FF anion-exchange columns 
(Amersham). The columns were equilibrated with 50mM 
Hepes, 10mM MgCl2, 1mM DTT, 1mM PMSF, 0.02% 
NaN3 (pH 7.5) and the target protein was eluted over a 
100ml 0-600mM NaCl linear gradient. The target fractions 
were then passed through a HiLoad Q-Sepharose column 
as  previously  described.  p23  was  then  further  purified 
on a HiPrep Sephacryl S-200 size-exclusion column Oncotarget 2011; 2:  43 - 58 55 www.impactjournals.com/oncotarget
as previously described, eluting in two distinct peaks 
corresponding to the dimeric and monomeric species. The 
chromatography standards used in the linear regression 
included IgG (Mr 160 kDa), BSA (Mr 67), β-lactoglobulin 
(Mr 35), lysozyme (Mr 15 kDa), cytochrome C (Mr 12.4 
kDa) and cytidine (Mr 240 Da) which elute at 48, 56, 66, 
74, 78 and 120 ml, respectively.
All proteins were dialyzed extensively against 
50mM Hepes 50mM KCl 10mM MgCl2 (pH 7.4) prior 
to storage at -80°C. The homogeneity of the proteins 
was  determined  by  SDS-PAGE  and  the  Experion™ 
Automated Electrophoresis station (BIO-RAD). Protein 
concentrations were determined spectrophotometrically 
via BCA assay.
Native-PAGE analysis
All individual protein samples and protein mixtures 
were resolved by 7.5% polyacrylamide in which no 
detergents, reducing or denaturing agents were used in 
any of the resolving, stacking or loading buffers. 5µg of 
total protein was loaded into each well with the Hsp90, 
FKBP52, HOP and p23 proteins being mixed together 
in their designated 2:1:2:2 molar ratios in the respective 
experiments. All protein complex mixtures were incubated 
at 30°C for 60 minutes as indicated in previous studies [7, 
51, 55]. The samples were not treated with heat prior to 
loading and all electrophoresis was done on ice
Immunoprecipitation pull-down assays
In each experiment 25µl of Protein A-Sepharose 
beads (GE) was equilibrated with 40µg of monoclonal 
Hsp90 (H90-10) antibody at room temperature for 30 
minutes in a 50mM Hepes, 50mM KCl, 10mM MgCl2 
, 1mM DTT solution (pH 7.4). The beads were washed 
multiple times and recovered by centrifugation prior to 
loading 40µg of Hsp90α bait protein. To test the specificity 
of the Hsp90 antibody 40µg of p23, FKBP52 and HOP were 
alternatively added in separate negative control reactions. 
The antibody/protein mixtures were incubated for 1 hour 
on ice with the pellets being harvested by centrifugation 
and washed multiple times in the previously described 
buffering system. To assess the simultaneous binding 
of FKBP52 and HOP to Hsp90, Hsp90-bound antibody/
Protein  A  beads  were  saturated  with  five-fold  molar 
excesses of each of the respective proteins in a step-wise 
fashion. At each step the protein mixtures were incubated 
at 30°C for 60 minutes with gentle shaking occurring 
every five minutes. After the first incubation the beads 
were washed extensively prior to another five-fold molar 
excess addition of the second TPR domain-containing 
protein. In additional experiments the p23, FKBP52, and 
HOP proteins were added to the Hsp90 bait in equimolar 
amounts according to the 2:1:2:2 molar binding ratios 
in the Hsp90-FKBP52-p23-HOP complex. The protein 
mixtures were incubated at 30°C for 60 minutes with 
gentle shaking occurring every 5 minutes. The buffering 
system was augmented with a 5mM ATP, 20mM Na2MoO4 
supplement and a 0.01% dose of the non-ionic detergent 
dodecyl-maltopyranoside in respective experiments. All 
unbound proteins were washed away from the Hsp90 bait 
with multiple washes and the harvested beads carrying 
Hsp90 and the bound complex constituents were resolved 
by 10% SDS-PAGE.
Analytical Size-Exclusion Chromatography
A 200 µl sample of 18µg/µl Hsp902-FKBP521-
p232-HOP2 complex was passed through a Superose6 
size-exclusion column (Amersham). The complex was 
separated from unbound constituent proteins over a 50ml 
elution period using a 50mM Hepes, 50mM KCl, 10mM 
MgCl2, 1mM PMSF, 1Mm DTT, 0.02% NaN3 buffer. The 
chromatography results were visualized by 10% SDS-
PAGE. The chromatography standards used in the linear 
regression included thyroglobulin (Mr 669 kDa), ferritin 
(Mr 440), aldolase (Mr 158), ovalbumin (Mr 43 kDa), 
carbonic anhydrase (Mr 29 kDa) and RNAse A (Mr 13.7 
kDa) which elute at 13, 14.5, 17, 18, 18.5 and 19 ml, 
respectively.
Dynamic Light Scattering
The diameter of the solvation layers surrounding 
each of the constituent proteins (hydrodynamic diameter) 
was  measured  in  the  Zetasizer  Nano  series  system 
(Malvern). 0.02mg/ml samples of each of the individual 
proteins were measured at 30°C with measurements 
occurring every 15 seconds for a total of 50 measurements 
with the total incubation time lasting 60 minutes. 
Complex formation as a function of time was analyzed 
over the course of 90 minutes in a 50mM Hepes, 50mM 
KCl, 10mM MgCl2, 1Mm DTT solution (pH 7.4) with and 
without the addition of the 5mM ATP, 20mM Na2MoO4 
and detergent supplements. The step-wise formation of 
the Hsp902-FKBP521-p232-HOP2 complex was analyzed 
in  the  aforementioned  buffer  with  the  ATP,  Na2MoO4 
and detergent supplements in which measurements were 
taken over the course of 60 minutes at each step. The 
degree of non-specific binding with Hsp90 was assessed 
with a 0.02mg/ml sample of Hsp90 in a 1:1 molar ratio 
with bovine serum albumin in which measurements 
were taken over a 60 minute time course. The accuracy 
and reproducibility of each experiment was analyzed by 
standard deviation within a 95% confidence interval.
Electron MicroscopyOncotarget 2011; 2:  43 - 58 56 www.impactjournals.com/oncotarget
The p23, FKBP52, HOP and Hsp90 proteins were 
diluted down from their respective 7, 9, 8, and 9 mg/ml 
concentrations to a final complex concentration of 0.02 
mg/ml by mixing the constituents together according 
to their molar ratios in the Hsp902-FKBP521-p232-
HOP2 complex. The individual proteins were incubated 
together at 30°C for 60 minutes as previously indicated 
in DLS experiments. The sample was blotted onto carbon 
grids and stained with 2% Methyl-amine tungstate. 
The images were collected on a Hitachi transmission 
electron microscope operating at a voltage of 80,000 V. 
CCD images were collected at 100,000x magnification. 
Individual particles were boxed from the micrograph 
using the BOXER program within the EMAN software 
suite [58]. As a reference images of individual unbound 
Hsp90 particles were prepared as previously described 
and were collected on a JEOL JEM 3200FS transmission 
electron microscope operating at 300,000 V. CCD images 
were collected at 80,000x magnification.
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